IP Library Granted Patent US 8,455,022
Granted Patent B2
US 8,455,022 · App. 13/051,593 · Granted Jun 4, 2013

Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin

Inventor: Eggert Stockfleth (Albersdorf, DE)
Assignee: MediGene AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,455,022
App. No.
13/051,593
Granted
Jun 4, 2013
Kind
B2
Abstract

The present invention refers to a method for treating cancerous or precancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.

Claims (14)

1. A method for treating a lesion of the skin in a patient, wherein said skin lesion is molluscum contagiosum, said method comprising topically administering a pharmaceutically effective amount of a polyphenol composition comprising (i) a mixture of polyphenols and (ii) a carrier, wherein the composition comprises from about 5% (w/w) to about 20% (w/w) of the mixture of polyphenols, wherein the mixture of polyphenols contains epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, and qallocatechol gallate.

2. The method according to claim 1 , wherein the patient is a human.

3. The method according to claim 1 , wherein the mixture of polyphenols is isolated from tea or a tea extract.

4. The method according to claim 3 , wherein the tea is a green tea.

5. The method according to claim 3 , wherein the tea extract is a green tea extract.

6. The method according to claim 1 , wherein the mixture of polyphenols contains (−)-epicatechol, (−)-epicatechol gallate, (−)-epigallocatechol, (−)-epigallocatechol gallate, (+) gallocatechol and/or (−)-gallocatechol gallate.

7. The method according to claim 6 , wherein the mixture of polyphenols contains about 2-20% (w/w) epicatechol, about 2-20% (w/w) epicatechol gallate, about 1-25% (w/w) epigallocatechol, about 40-75% (w/w) epigallocatechol gallate, and about 0.5-20% (w/w) gallocatechol gallate.

8. The method according to claim 6 , wherein the mixture of polyphenols contains about 10.8% (w/w) of epicatechol, about 6.5% (w/w) of epicatechol gallate, about 9.2% (w/w) of epigallocatechol, about 54.8% (w/w) of epigallocatechol gallate and/or about 4.0% (w/w) of gallocatechol gallate.

9. The method according to claim 6 , wherein the mixture of polyphenols contains about 10.8% (w/w) of (−)-epicatechol, about 6.5% (w/w) of (−)-epicatechol gallate, about 9.2% (w/w) of (−)-epigallocatechol, about 54.8% (w/w) of (−)-epigallocatechol gallate and about 4.0% (w/w) of (−)-gallocatechol gallate.

10. The method according to claim 1 , wherein the mixture of polyphenols is combined with an additive.

11. The method according to claim 10 , wherein the additive is selected from the group consisting of petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate, propylene glycol monopalmitostearate and/or isopropyl myristate.

12. The method according to claim 1 , wherein the mixture of polyphenols is contained in a carrier selected from the group consisting of an emulsion, a gel, a cream and/or an ointment.

13. The method according to claim 1 , wherein the composition comprises about 15% (w/w) mixture of polyphenols.

14. A method for treating a lesion of the skin in a patient, wherein said skin lesion is molluscum contagiosum, said method comprising topically administering a pharmaceutically effective amount of a polyphenol composition comprising (i) a mixture of polyphenols and (ii) a carrier, wherein the composition comprises about 15% (w/w) mixture of polyphenols, wherein the mixture of polyphenols contains about 10.8% (w/w) of (−)-epicatechol, about 6.5% (w/w) of (−)-epicatechol gallate, about 9.2% (w/w) of (−)-epigallocatechol, about 54.8% (w/w) of (−)-epigallocatechol gallate, and about 4.0% (w/w) of (−)-gallocatechol gallate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: MEDIGENE AG
To: FOUGERA PHARMACEUTICALS INC
Reel/Frame 044603/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2011
From: STOCKFLETH, EGGERT
To: MEDIGENE AG
Reel/Frame 027094/0482 →
Continuity (3)
Continuation 10574422
Provisional Application 60510101 · Oct 9, 2003
Related Publication 20110166219A1 · Jul 7, 2011